|
| |
IntegriumIntegrium is a well-established contract research organization providing a comprehensive range of product research, development, and communication services to clients in the pharmaceutical, biotechnology and medical device industries. We design and manage clinical trials for purposes of product registration and product positioning. Integrium also provides integrated and turnkey solutions and strategies aimed at maximizing product positioning, differentiation and visibility in the marketplace and meeting sales and marketing objectives. As industry development timelines are increasingly compressed, and as marketing expenditures are more frequently measured against return on investment, today's decision makers in the biopharmaceutical industry require service providers and partners with bias for initiative and action, combined with operational and financial efficiency. Further, these service attributes must be combined with a focus on quality, integrity and solid scientific and regulatory guidance. Integrium was founded and is guided by physicians with substantial experience in the scientific development, analysis, reporting, and promotional areas of the biopharmaceutical industry and offers intelligent and integrated services conducted by professional, proactive team members. We have developed an impressive track record of performance in trial management services for our clients and providing strategic innovation to our clients.
| Contact Details: |
| 14351 Myford Road |
| Tustin |
| California |
| 92780 |
| United States of America |
| Tel: | 714.541.5591 |
| Fax: | 714.541.5601 |
| Email: | info@integrium.com |
| WWW: | www.integrium.com/

|
|
Loading...
|
Recent Publications by Integrium: |  |
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.
Hypertension is a major health problem worldwide, yet remains... | 22nd October, 2008
| Integrium,
| Drugs. 2008;68(9):1207-25.
|
Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
Angiotensin receptor antagonists (angiotensin receptor blockers; ARBs) are... | 2nd April, 2008
| Integrium,
| Am J Cardiovasc Drugs. 2007;7(5):347-56.
|
Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same?
Hypertension is a multifactorial disorder leading to pathophysiologic... | 7th March, 2008
| Orange County Research Center, Tustin, California, USA.
| Am J Cardiovasc Drugs. 2007;7(6):413-22.
|
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
INTRODUCTION: Goal rates, the percentage of patients with hypertension... | 21st April, 2005
| Integrium,
| Am J Cardiovasc Drugs. 2005;5(1):41-50.
|
Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements.
OBJECTIVE: This meta-analysis aimed to determine whether ambulatory blood... | 7th April, 2004
| Integrium,
| J Hypertens. 2003 Jul;21(7):1291-8.
DOI Direct Link |
→View more Integrium research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 428 times since April 2007, the link to the organisation's website has been followed 59 times Recent Search Terms used to find this page: integrium scientific | integrium financial | Integrium | integrium | . Search for more companies in Tustin Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Integrium |